Nordic Nanovector

319 articles with Nordic Nanovector

• Nordic Nanovector ASA: Annual General Meeting held - Apr 28, 2021

  4/28/2021

  The Annual General Meeting of Nordic Nanovector ASA was held on 28 April 2021 in Oslo, Norway.

• Nordic Nanovector ASA: Notice of Annual General Meeting on 28 April 2021

  4/7/2021

  Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2021 , at 14:00 hours CEST at Kjelsåsveien 168 B 0884 Oslo.

• Nordic Nanovector ASA Announces Proposed Board Change - Apr 07, 2021

  4/7/2021

  Nordic Nanovector ASA announces that its Nomination Committee has nominated Mrs Solveig Hellebust for election as a Non-executive Director at the Company's Annual General Meeting on 28 April 2021.

• Nordic Nanovector ASA publishes 2020 Annual Report

  3/29/2021

  On 26 March 2021, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2020.

• Nordic Nanovector ASA - allocation of PSUs - Mar 26, 2021

  3/26/2021

  The Board of Directors of Nordic Nanovector ASA has on 26 March 2021 decided to grant 1,070,000 Performance Share Units to employees in accordance with the authorisation granted at the Annual General Meeting held on 10 June 2020.

• Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer

  3/18/2021

  Nordic Nanovector ASA announces the appointment of Peter L. Braun as Chief Executive Officer.

• Nordic Nanovector to present at Carnegie's upcoming Nordic Virtual Healthcare Seminar 2021

  3/9/2021

  Nordic Nanovector ASA announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Carnegie's upcoming Nordic Virtual Healthcare Seminar 2021, taking place 9-12 March 2021.

• Nordic Nanovector to present at 11th Annual World ADC Europe 2021 Digital

  3/8/2021

  Nordic Nanovector ASA announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 9 March at the 11th Annual World ADC Europe 2021 Digital event in the Discovery stream discussing the question: Should Payloads be Super-Potent?

• Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2020

  2/18/2021

  Nordic Nanovector ASA announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic Nanovector's management team will take place at 08.30 CET.

• Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

  2/18/2021

  Nordic Nanovector ASA provides an update on PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® in 3rd-line relapsed/refractory follicular lymphoma.

• Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2020 Results Presentation and Webcast

  2/15/2021

  Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the fourth quarter and full year 2020 on Thursday, 18 February 2021 .

• Nordic Nanovector - Financial Calendar 2021

  12/21/2020

  Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

• Nordic Nanovector to Present at DNB's 11th Annual Nordic Healthcare Conference

  12/7/2020

  Nordic Nanovector ASA announces that its Interim CEO, Dr Lars Nieba will present a corporate overview via live webcast at DNB's 11th Annual Nordic Healthcare Conference, taking place on 15 December 2020.

• Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma

  12/1/2020

  Nordic Nanovector ASA announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.

• Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV'

  11/30/2020

  Nordic Nanovector ASA announces that the Company's ticker symbol on the Oslo Børs will change from 'NANO' to 'NANOV' and will be effective as of the start of trading on 30 November 2020.

• Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial

  11/19/2020

  Nordic Nanovector ASA announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 trial investigating safety and preliminary efficacy of Betalutin® in combination with rituximab in 2nd-line follicular lymphoma.

• Nordic Nanovector ASA: Results for the Third Quarter 2020

  11/19/2020

  Nordic Nanovector ASA announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place in Oslo at 08.30 CET, see details below.

• Nordic Nanovector to Present at Upcoming Jefferies Virtual London Healthcare Conference

  11/16/2020

  Nordic Nanovector ASA announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Jefferies Virtual London Healthcare Conference, taking place 17-19 November 2020.

• Nordic Nanovector ASA: Invitation to Q3 2020 Results Presentation and Webcast

  11/16/2020

  Nordic Nanovector ASA announces that it will report its results for the third quarter 2020 on Thursday, 19 November 2020.

• Nordic Nanovector ASA: Extraordinary general meeting held - Oct 21, 2020

  10/21/2020

  Nordic Nanovector ASA announces that an extraordinary general meeting in the Company was held at the Company's offices in Kjelsåsveien 168B, 0884 Oslo.